Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.
| Autor: | Podany, Anthony T, Cramer, Yoninah, Imperial, Marjorie, Rosenkranz, Susan L, Avihingsanon, Anchalee, Arduino, Roberto, Samaneka, Wadzanai, Gelmanova, Irina, Savic, Rada, Swindells, Susan, Dawson, Rodney, Luetkemeyer, Anne F |
|---|---|
| Předmět: |
DRUG therapy for tuberculosis
TUBERCULOSIS prevention HIV prevention COMBINATION drug therapy RESEARCH funding ISONIAZID DRUG administration CLINICAL trials HIV infections DESCRIPTIVE statistics ANTITUBERCULAR agents PSYCHOLOGY of HIV-positive persons HIGHLY active antiretroviral therapy RESEARCH ANTI-HIV agents CONFIDENCE intervals |
| Zdroj: | Clinical Infectious Diseases; 10/15/2024, Vol. 79 Issue 4, p983-989, 7p |
| Abstrakt: | Background One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for tuberculosis prevention in people with human immunodeficiency virus (HIV). However, rifapentine may decrease antiretroviral drug concentrations and increase the risk of virologic failure. AIDS Clinical Trials Group A5372 evaluated the effect of 1HP on the pharmacokinetics of twice-daily dolutegravir. Methods A5372 was a multicenter, pharmacokinetic study in people with HIV (≥18 years) already on dolutegravir-containing antiretroviral therapy with HIV RNA <50 copies/mL. Participants received daily rifapentine/isoniazid (600 mg/300 mg) for 28 days as part of 1HP. Dolutegravir was increased to 50 mg twice daily during 1HP, and intensive pharmacokinetic sampling was performed on day 0 (before 1HP) and on the final day of 1HP treatment. Results Thirty-two participants (41% female; 66% Black/African; median [Q1, Q3] age, 42 [34, 49] years) were included in the pharmacokinetic analysis; 31 had HIV RNA <50 copies/mL at the end of 1HP dosing. One participant had an HIV RNA of 160 copies/mL at day 28, with HIV RNA <50 copies/mL upon repeat testing on day 42. The median (Q1, Q3) dolutegravir trough concentration was 1751 ng/mL (1195, 2542) on day 0 versus 1987 ng/mL (1331, 2278) on day 28 (day 28:day 0 geometric mean ratio, 1.05 [90% confidence interval,.93–1.2]; P =.43). No serious adverse events were reported. Conclusions Dolutegravir trough concentrations with 50 mg twice-daily dosing during 1HP treatment were greater than those with standard-dose dolutegravir once daily without 1HP. These pharmacokinetic, virologic, and safety data provide support for twice-daily dolutegravir use in combination with 1HP for tuberculosis prevention. Clinical Trials Registration NCT04272242. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|